Top Story

Aflibercept decreases exudation, does not improve VA in previously treated AMD

October 30, 2014

Aflibercept decreased exudation in patients with persistent age-related macular degeneration after treatment with other anti-VEGFs, but visual acuity did not improve, according to a study.

The retrospective study included 67 eyes of 63 patients with exudative AMD who were treated with Eylea (aflibercept, Regeneron) for persistent exudation after having received at least three injections of Lucentis (ranibizumab, Genentech) or Avastin (bevacizumab, Genentech).

In the Journals

AMD severity in first eye foretells incidence, progression in fellow eye

October 29, 2014
Severity of age-related macular degeneration in one eye was associated with an increased incidence of disease and progression in the fellow eye, according to study…

Allegro enrolls patients in phase 2 trial of Luminate for DME

October 29, 2014
Allegro Ophthalmics announced that it is enrolling 150 patients in a phase 2 trial to assess Luminate, previously known as ALG-1001, for patients with diabetic…
figure Meeting News CoverageVideo

Patient selection key in treating VMA with Jetrea

October 27, 2014
CHICAGO — At the American Academy of Ophthalmology, Jay S. Duker, MD, discusses patient selection parameters for consideration in using ocriplasmin for the…
CME
figure

Postoperative Inflammation and Pain: Elimination of the Dynamic Duo to Improve Patient Outcomes

This activity is supported by an educational grant from Bausch + Lomb.

Cataract surgery has improved in both safety and outcomes in recent years. With advances in surgical techniques…
More »
Meeting News Coverage Video
figure

Patient selection key in treating VMA with Jetrea

October 27, 2014
CHICAGO — At the American Academy of Ophthalmology, Jay S. Duker, MD, discusses patient selection parameters for…
More »

Filter By:

In the Journals

Aflibercept decreases exudation, does not improve VA in previously treated AMD

October 30, 2014
Aflibercept decreased exudation in patients with persistent age-related macular degeneration after treatment with other anti-VEGFs, but visual acuity…
In the Journals

AMD severity in first eye foretells incidence, progression in fellow eye

October 29, 2014
Severity of age-related macular degeneration in one eye was associated with an increased incidence of disease and progression in the fellow eye…

Allegro enrolls patients in phase 2 trial of Luminate for DME

October 29, 2014
Allegro Ophthalmics announced that it is enrolling 150 patients in a phase 2 trial to assess Luminate, previously known as ALG-1001, for…
figure Meeting News Coverage Video

Patient selection key in treating VMA with Jetrea

October 27, 2014
CHICAGO — At the American Academy of Ophthalmology, Jay S. Duker, MD, discusses patient selection parameters for consideration in using…
Perspectives on Glaucoma

Diabetes associated with increased glaucoma risk, researchers report

October 24, 2014
Diabetes, diabetes duration and fasting glucose levels are associated with a significantly increased risk of glaucoma, according to a study recently…

Prevent Blindness increases attention toward diabetic eye disease

October 24, 2014
Prevent Blindness has declared November as Diabetic Eye Disease Awareness Month to assist in educating the public on diabetes prevention plans…

Positive ongoing results in phase 1/2 trial in noninfectious uveitis

October 23, 2014
Seven out of eight patients with noninfectious uveitis receiving a suprachoroidal injection of triamcinolone acetonide achieved clinically meaningful…

Brien Holden Vision Institute to launch commercial entities

October 21, 2014
The Brien Holden Vision Institute is in the process of bringing to market advanced products for myopia and myopia control, presbyopia, and the…
figure Meeting News Coverage

Clinical trials accumulate data for novel anti-VEGF

October 21, 2014
CHICAGO — A new anti-VEGF indicated for use in wet age-related macular degeneration achieved clinically meaningful and durable vision…

Stem cell-derived RPE cells shown to be safe in patients with AMD

October 21, 2014
Advanced Cell Technology Inc. announced that phase 1/2 clinical data showed positive long-term safety when ACT’s retinal pigment epithelium…
More Headlines »